Stories
Slash Boxes
Comments

SoylentNews is people

posted by Fnord666 on Sunday July 16 2017, @06:09AM   Printer-friendly
from the bespoke-treatments dept.

Arthur T Knackerbracket has found the following story:

A new era of treating disease has moved a step closer to reality in the United States.

A Food and Drug Administration panel gave a thumbs-up Wednesday to a gene therapy that involves genetically engineering a patient's T-cells to fight a particular type of leukemia, The New York Times reports.

If the FDA agrees with the panel's recommendation and moves to approve the treatment for commercial use, it would be the first such gene-altering treatment to make it to market.

[...] Once the stuff of science fiction, altering human genes has been creeping into reality of late. Also on Wednesday, researchers at Harvard announced they'd managed to encode video files into the genetic material of living cells, demonstrating the viability of a "molecular recorder" that could lead to more disease treatments in the future.

-- submitted from IRC


Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 0) by Anonymous Coward on Sunday July 16 2017, @06:54AM (1 child)

    by Anonymous Coward on Sunday July 16 2017, @06:54AM (#539824)

    Well, Novartis needs to make up for all the money lost chasing obvious dead ends so it will be 300k per session or whatever. Also, I didn't read the papers (yet) but HIV can do cell-to-cell transmission...

  • (Score: 2, Interesting) by Anonymous Coward on Sunday July 16 2017, @04:17PM

    by Anonymous Coward on Sunday July 16 2017, @04:17PM (#539924)

    The vectors are self-inactivating (the 3' LTR will be unable to produce a replication competent genome) and the envelope proteins are produced separately (not present in the viral genome). The structural, enzymatic, and accessory viral proteins are also produced separately.